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Department of Medical Oncology, Institut Gustave-Roussy, rue Camille Desmoulins, 94805 Villejuif, FranceAs physicians today, we are fortunate to benefit from rapid
advances in scientific discovery. More than 50 years elapsed
between Pasteur’s discovery of microbes as the agents of
infectious disease and Fleming’s discovery of the first antibac-
terial agent. Today, this process is remarkably accelerated,
with little if any lag between the identification of a potential
target and the development of a drug directed against it. Can-
cer drug development in particular is entering a remarkable
new phase following advances in molecular biology that have
enabled new approaches to targeting cancer cells or their
microenvironment. This supplement presents the proceed-
ings of ‘Bringing Discovery to Light’, an official satellite sym-
posium of the 13th European Cancer Conference (ECCO) held
in Paris, on Wednesday 2 November, 2005. The purpose of the
symposium was to explore some of the research being con-
ducted at the forefront of cancer medicine and to highlight
new therapies that are becoming available as a result.
Dr Maria Kavallaris considered several strategies for over-
coming the clinical problem of resistance to antimicrotubule
cytotoxics, which remain among the most clinically impor-
tant anticancer therapies. These include the development of
new tubulin-binding agents, such as the epothilone ana-
logues, which are proving effective against taxane-resistant
tumours, as well as investigating how changes in microtubule
stability might be exploited to improve treatment response,1359-6349/$ - see front matter  2006 Elsevier Ltd. All rights reserved
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1 Medical Director IGR&D.and how antimicrotubule drug resistance might potentially
be overcome by gene silencing or small molecule approaches
that target specific regulators of microtubule function.
Professor Karol Sikora provided a panoramic view of the
increasing importance of immunology in advancing cancer
medicine, both as a tool in drug development and diagnos-
tics, and as the basis for new targeted therapies and specific
immunotherapy. He considered how immunology in its
broad sense might help to overcome some of the challenges
involved in realising the huge promise of new anticancer
therapies within the constraints of modern healthcare
provision.
In recent years substantial advances have been made in
understanding the fundamental biology of tumorigenesis,
resulting in a number of new targets for small molecule inhib-
itors. Professor Juan Carlos Lacal reviewed the rationale for
targeting the tyrosine kinases, the development of the tyro-
sine kinase inhibitors, and some of the clinical evidence for
the efficacy of these drugs in the management of cancer.
Professor Lacal sounded an optimistic note for the future
of cancer management by suggesting that it is only a matter
of time before all cancers can be treated effectively. Certainly
on the evidence of the information presented here, cautious
optimism appears justified, while much of course remains
to be achieved..
